Show simple item record

FieldValueLanguage
dc.contributor.authorYu XQen
dc.contributor.authorLuo Qen
dc.contributor.authorSmith DPen
dc.contributor.authorClements MSen
dc.contributor.authorPatel MIen
dc.contributor.authorO'Connell DLen
dc.date.issued2017
dc.date.issued2017en
dc.identifier.urihttps://hdl.handle.net/2123/30674
dc.description.abstractTo develop a method for estimating the future numbers of prostate cancer survivors requiring different levels of care. DESIGN, SETTING AND PARTICIPANTS: Analysis of population-based cancer registry data for prostate cancer cases (aged 18-84 years) diagnosed in 1996-2007, and a linked dataset with hospital admission data for men with prostate cancer diagnosed during 2005-2007 in New South Wales (NSW), Australia. METHODS: Cancer registry data (1996-2007) were used to project complete prostate cancer prevalence in NSW, Australia for 2008-2017, and treatment information from hospital records (2005-2007) was used to estimate the inpatient care needs during the first year after diagnosis. The projected complete prevalence was divided into care needs-based groups. We first divided the cohort into two groups based on patient's age (<75 and 75-84 years). The younger cohort was further divided into initial care and monitoring phases. Cause of death data were used as a proxy for patients requiring last year of life prostate cancer care. Finally, episode data were used to estimate the future number of cases with metastatic progression. RESULTS: Of the estimated total of 60,910 men with a previous diagnosis of prostate cancer in 2017, the largest groups will be older patients (52.0%) and younger men who require monitoring (42.5%). If current treatment patterns continue, in the first year post-diagnosis 41% (1380) of patients (<75 years) will have a radical prostatectomy, and 52.6% (1752) will be likely to have either active surveillance, external beam radiotherapy or androgen deprivation therapy. About 3% will require care for subsequent metastases, and 1288 men with prostate cancer are likely to die from the disease in 2017. CONCLUSIONS: This method extends the application of routinely collected population-based data, and can contribute much to the knowledge of the number of men with prostate cancer and their health care requirements. This could be of significant use in planning future cancer care services and facilities in Australia.en
dc.description.sponsorshipAcknowledgments We would like to thank the NSW Cancer Registry for providing the primary data for this study, the NSW Ministry of Health for providing the NSW Admitted Patient Data Collection, the NSW Centre for Health Record Linkage for conducting record linkage, and Clare Kahn for editorial assistance.
dc.publisherPLoS ONEen
dc.rightsOther
dc.subject.otherCancer Type - Prostate Canceren
dc.subject.otherTreatment - Resources and Infrastructureen
dc.titlePhase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study.en
dc.typeArticleen
dc.identifier.doi10.1371/journal.pone.0171013
dc.relation.otherThis study was funded by the Prostate Cancer Foundation of Australia (PCFA – YI 0410) (to Xue Qin Yu). David Smith was supported by an Australian NHMRC Early Career Fellowship (App1016598).en
usyd.facultyFaculty of Medicine and Health, The Daffodil Centreen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.